Emin Avşar

1.0k total citations
18 papers, 637 citations indexed

About

Emin Avşar is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Emin Avşar has authored 18 papers receiving a total of 637 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Emin Avşar's work include Lung Cancer Treatments and Mutations (8 papers), Colorectal Cancer Treatments and Studies (5 papers) and Heat shock proteins research (3 papers). Emin Avşar is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Colorectal Cancer Treatments and Studies (5 papers) and Heat shock proteins research (3 papers). Emin Avşar collaborates with scholars based in United States, Spain and France. Emin Avşar's co-authors include Ruth M. Empson, Leena Gandhi, Edward B. Garon, Yumin Zhao, Karim A. Benhadji, Michael Man, Susan C. Guba, Shawn T. Estrem, Benjamin Besse and Ivelina Gueorguieva and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Emin Avşar

17 papers receiving 630 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Emin Avşar United States	11	379	302	144	116	81	18	637
Abbey L. Wentzel United States	9	344 0.9×	335 1.1×	84 0.6×	59 0.5×	63 0.8×	10	568
Meejeon Roh United States	14	254 0.7×	407 1.3×	133 0.9×	111 1.0×	145 1.8×	21	740
Rajesh Patel United States	9	176 0.5×	302 1.0×	55 0.4×	55 0.5×	95 1.2×	20	604
Christo Kole Greece	11	319 0.8×	277 0.9×	107 0.7×	153 1.3×	41 0.5×	17	668
Patrick Eulitt United States	8	154 0.4×	223 0.7×	73 0.5×	67 0.6×	26 0.3×	18	474
Xiaochun Yu United States	11	424 1.1×	495 1.6×	65 0.5×	114 1.0×	17 0.2×	20	725
Daniel J. García-Domínguez Spain	13	150 0.4×	363 1.2×	134 0.9×	58 0.5×	49 0.6×	29	502
Guotai Xu United States	10	215 0.6×	482 1.6×	62 0.4×	42 0.4×	24 0.3×	13	646
Chetan K. Rane United States	8	174 0.5×	305 1.0×	61 0.4×	38 0.3×	31 0.4×	12	512
Michela Cortesi Italy	15	192 0.5×	291 1.0×	98 0.7×	61 0.5×	9 0.1×	25	651

Countries citing papers authored by Emin Avşar

Since Specialization

Citations

This map shows the geographic impact of Emin Avşar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emin Avşar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emin Avşar more than expected).

Fields of papers citing papers by Emin Avşar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emin Avşar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emin Avşar. The network helps show where Emin Avşar may publish in the future.

Co-authorship network of co-authors of Emin Avşar

This figure shows the co-authorship network connecting the top 25 collaborators of Emin Avşar. A scholar is included among the top collaborators of Emin Avşar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emin Avşar. Emin Avşar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Ray-Coquard, Isabelle Laure, David M. O’Malley, Bhavana Pothuri, et al.. (2025). Initial results from a first-in-human phase 1 study of LY4170156, an ADC targeting folate receptor alpha (FRα), in advanced ovarian cancer and other solid tumors.. Journal of Clinical Oncology. 43(16_suppl). 3023–3023.

Nadal, Ernest, Mansoor N. Saleh, Santiago Ponce Aix, et al.. (2023). A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer. BMC Cancer. 23(1). 708–708. 36 indexed citations

Pennell, Nathan A., Lori J. Wirth, Justin F. Gainor, et al.. (2022). A first-in-human phase 1 study of the next-generation RET inhibitor, LOXO-260, in RET inhibitor refractory patients with RET-altered cancers (trial in progress).. Journal of Clinical Oncology. 40(16_suppl). TPS8595–TPS8595. 12 indexed citations

Melisi, Davide, Do‐Youn Oh, Antoine Hollebecque, et al.. (2021). Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer. Journal for ImmunoTherapy of Cancer. 9(3). e002068–e002068. 149 indexed citations

Kluger, Harriet M., Sarah A. Weiss, Anthony J. Olszanski, et al.. (2019). Abstract CT089: Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC). Clinical Trials. CT089–CT089. 2 indexed citations

Kluger, Harriet M., Sarah A. Weiss, Anthony J. Olszanski, et al.. (2019). Abstract CT089: Phase Ib/II of CD40 agonistic antibody APX005M in combination with nivolumab (nivo) in subjects with metastatic melanoma (M) or non-small cell lung cancer (NSCLC). Cancer Research. 79(13_Supplement). CT089–CT089. 10 indexed citations

Malhotra, Jyoti, Petros Nikolinakos, Ticiana Leal, et al.. (2019). Ph1/2 study of Rova-T in combination with nivolumab (Nivo) ± ipilimumab (Ipi) for patients (pts) with 2L+ extensive-stage (ED) SCLC.. Journal of Clinical Oncology. 37(15_suppl). 8516–8516. 11 indexed citations

Felip, Enriqueta, Fabrice Barlési, Benjamin Besse, et al.. (2017). Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 13(4). 576–584. 69 indexed citations

Tabernero, Josep, Robin M.J.M. van Geel, Tormod Kyrre Guren, et al.. (2016). O-026 Combination of encorafenib and cetuximab with or without alpelisib in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC): phase 2 results. Annals of Oncology. 27. ii127–ii127. 5 indexed citations

10.

Tabernero, Josep, Robin M.J.M. van Geel, Tormod Kyrre Guren, et al.. (2016). Phase 2 results: Encorafenib (ENCO) and cetuximab (CETUX) with or without alpelisib (ALP) in patients with advanced BRAF-mutant colorectal cancer (BRAFm CRC).. Journal of Clinical Oncology. 34(15_suppl). 3544–3544. 82 indexed citations

11.

Schellens, Jan H.M., Robin M.J.M. van Geel, Johanna C. Bendell, et al.. (2015). Abstract CT136: Final biomarker analysis of the phase I study of the selective BRAF V600 inhibitor encorafenib (LGX818) combined with cetuximab with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF-mutant colorectal cancer. Cancer Research. 75(15_Supplement). CT136–CT136. 8 indexed citations

12.

Tabernero, Josep, Robin M.J.M. van Geel, Anna Spreafico, et al.. (2014). 11LBA Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor alpelisib (BYL719) in patients with advanced BRAF mutant colorectal cancer. European Journal of Cancer. 50. 199–199. 9 indexed citations

13.

Geel, Robin M.J.M. van, Élena Elez, Johanna C. Bendell, et al.. (2014). Phase I study of the selective BRAF^V600inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer.. Journal of Clinical Oncology. 32(15_suppl). 3514–3514. 37 indexed citations

14.

Garon, Edward B., Richard S. Finn, Habib Hamidi, et al.. (2013). The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth. Molecular Cancer Therapeutics. 12(6). 890–900. 56 indexed citations

15.

Garon, Edward B., Teresa Morán, Fabrice Barlési, et al.. (2012). Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 30(15_suppl). 7543–7543. 34 indexed citations

16.

Felip, Enriqueta, Enric Carcereny, Fabrice Barlési, et al.. (2012). Phase II Activity of the HSP90 Inhibitor AUY922 in Patients with Alk-Rearranged (ALK+) or Egfr-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC). Annals of Oncology. 23. ix152–ix152. 45 indexed citations

17.

Arslan, Ferhat, Fehmı Tabak, Emin Avşar, et al.. (2010). Ganciclovir-resistant cytomegalovirus encephalitis in a hematopoietic stem cell transplant recipient. Journal of NeuroVirology. 16(2). 174–178. 9 indexed citations

18.

Avşar, Emin & Ruth M. Empson. (2004). Adenosine acting via A1 receptors, controls the transition to status epilepticus-like behaviour in an in vitro model of epilepsy. Neuropharmacology. 47(3). 427–437. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact